MMDCF - Definium Therapeutics, Inc.
$—
0 n/a
Share volume: —
Last Updated: —
Pharmaceutical Products/Medicinal Chemicals:0.37%
Previous close—
Chg—
Chg%—%
-------
No prices for this period.
Key data
Stock priceN/A
P/E ratioN/A
Day range— - —
EPS$-3.44
52 week range— - —
52 week change— %
Market cap5.131 B
YieldN/A
Shares outstanding39.720 M
DividendN/A
Ex-dividend dateN/A
Next earnings dateN/A
BetaN/A
Public floatN/A
Average 10 volumeN/A
Average 30 volumeN/A
Company detail
- CEO
- Robert Barrow
- Region
- US
- Website
- mindmed.co
- Employees
- 40
- IPO year
- 2016
- Issue type
- —
- Market
- OTCM
- Industry
- Pharmaceutical Products/Medicinal Chemicals
- Sector
- Manufacturing
Mind Medicine (MindMed) Inc. develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder.